AstraZeneca PLC

AZN Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
AZN Income Statement
AZN Balance Sheet
AZN Cash Flow
Congress Trading

Recent trades of AZN by members of U.S. Congress

Politician Type Traded
Daniel S. Goldman House / D Sale $100,001 - $250,000 Jul. 10, 2023
Alan S. Lowenthal House / D Sale $1,001 - $15,000 Dec. 01, 2021
Dean Phillips House / D Exchange $1,001 - $15,000 Jul. 21, 2021
Sara Jacobs House / D Sale $15,001 - $50,000 Apr. 09, 2021
Alan S. Lowenthal House / D Purchase $962.54 Feb. 22, 2021
Alan S. Lowenthal House / D Purchase $1,001 - $15,000 Feb. 22, 2021
Alan S. Lowenthal House / D Purchase $15,001 - $50,000 Feb. 22, 2021
Greg Gianforte House / R Purchase $1,001 - $15,000 Dec. 01, 2020
Thomas R. Suozzi House / D Sale $15,001 - $50,000 Feb. 24, 2020
John H. Rutherford House / R Sale $1,001 - $15,000 Jan. 15, 2020
Thomas R. Suozzi House / D Purchase $15,001 - $50,000 Jan. 07, 2020
Mikie Sherrill House / D Sale $1,001 - $15,000 May. 28, 2019
Mikie Sherrill House / D Sale $1,001 - $15,000 May. 28, 2019
Mikie Sherrill House / D Sale $1,001 - $15,000 May. 28, 2019
Shelley Moore Capito Senate / R Sale (Full) $1,001 - $15,000 Mar. 11, 2019
Nicholas V. Taylor House / R Sale $1,001 - $15,000 Jan. 14, 2019
Nicholas V. Taylor House / R Sale $1,001 - $15,000 Jan. 07, 2019
Earl Blumenauer House / D Purchase $1,001 - $15,000 Mar. 07, 2018
Shelley Moore Capito Senate / R Purchase $1,001 - $15,000 Sep. 08, 2017
John H. Rutherford House / R Purchase $1,001 - $15,000 Jul. 11, 2017
Dwight Evans House / D Purchase $1,001 - $15,000 Dec. 30, 2016
Thomas MacArthur House / R Sale $15,001 - $50,000 Dec. 02, 2016
Thomas MacArthur House / R Sale $15,001 - $50,000 Aug. 12, 2016
Thomas MacArthur House / R Purchase $50,001 - $100,000 Feb. 22, 2016
Bob Corker Senate / R Sale (Full) $1,001 - $15,000 May. 20, 2014
K. Michael Conaway House / R Sale $1,001 - $15,000 May. 07, 2014
Bob Corker Senate / R Sale (Full) $1,001 - $15,000 Apr. 29, 2014
Michael K. Simpson House / R Sale $1,001 - $15,000 Apr. 25, 2014
Bob Corker Senate / R Sale (Full) $1,001 - $15,000 Apr. 21, 2014
Bob Corker Senate / R Sale (Full) $1,001 - $15,000 Apr. 21, 2014
Bob Corker Senate / R Purchase $1,001 - $15,000 Mar. 03, 2014
Bob Corker Senate / R Sale (Full) $1,001 - $15,000 Feb. 28, 2014
Bob Corker Senate / R Purchase $1,001 - $15,000 Jan. 08, 2014
AZN Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
AZN Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
AZN Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by AZN's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard
Corporate Lobbying

Government lobbying spending instances

  • $650,000 Oct 21, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
  • $950,000 Jul 22, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
  • $700,000 Apr 22, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
  • $80,000 Feb 07, 2024 Issue: Health Issues Medicare/Medicaid Pharmacy Budget/Appropriations
  • $830,000 Jan 22, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
  • $950,000 Oct 20, 2023 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Method for the manufacture of 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof Nov. 05, 2024
  • Patent Title: Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases Oct. 22, 2024
  • Patent Title: Glp-1 receptor ligand moiety conjugated oligonucleotides and uses thereof Oct. 15, 2024
  • Patent Title: Dendrimer formulations Oct. 15, 2024
  • Patent Title: Halo-substituted piperidines as orexin receptor modulators Sep. 10, 2024
  • Patent Title: Chemical compounds Sep. 03, 2024
  • Patent Title: Antibody molecules and conjugates Aug. 20, 2024
  • Patent Title: Method of treating type 1 interferon (ifn)-mediated disease using a subcutaneous dosing regimen comprising anifrolumab Aug. 13, 2024
  • Patent Title: Pharmaceutical compositions comprising (2s)-n-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide Aug. 13, 2024
  • Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Aug. 06, 2024
  • Patent Title: Pill dispenser Jul. 30, 2024
  • Patent Title: Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors Jul. 02, 2024
  • Patent Title: Methods for treating late-stage small cell lung cancer by administering a human anti-pd-l1 antibody, an etoposide and a platinum-based therapeutic Jun. 18, 2024
  • Patent Title: 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4h-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase May. 07, 2024
  • Patent Title: Methods of treating homologous recombination deficient cancer Apr. 30, 2024
  • Patent Title: Compounds and their use Apr. 30, 2024
  • Patent Title: Inhaler Apr. 23, 2024
  • Patent Title: Arginase inhibitors and methods of use thereof Apr. 09, 2024
  • Patent Title: Spirocyclic compounds Mar. 26, 2024
  • Patent Title: Arginase inhibitors and methods of use thereof Feb. 27, 2024
  • Patent Title: Methods of treating heart failure with reduced ejection fraction Feb. 20, 2024
  • Patent Title: Purinone compounds and their use in treating cancer Jan. 30, 2024
  • Patent Title: Inhaler Jan. 30, 2024
  • Patent Title: Substituted indazoles as irak4 inhibitors Jan. 09, 2024
  • Patent Title: N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides Jan. 02, 2024
  • Patent Title: Automated detection of safety signals for pharmacovigilance Dec. 19, 2023
  • Patent Title: Method of treating fatty liver disease Dec. 12, 2023
  • Patent Title: Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same Nov. 28, 2023
  • Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Nov. 14, 2023
  • Patent Title: Pharmaceutical composition Nov. 14, 2023
  • Patent Title: Chemical compounds Oct. 24, 2023
  • Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Oct. 03, 2023
  • Patent Title: Protein kinase b inhibitors Sep. 19, 2023
  • Patent Title: Mpo inhibitors for use in medicine Aug. 29, 2023
  • Patent Title: Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases Aug. 22, 2023
  • Patent Title: Therapeutic dendrimers Aug. 08, 2023
  • Patent Title: Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors Jul. 04, 2023
  • Patent Title: Biomarkers and methods of treating cancer Jun. 27, 2023
  • Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Jun. 20, 2023
  • Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Jun. 13, 2023
  • Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Jun. 13, 2023
  • Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Jun. 06, 2023
  • Patent Title: Compounds and their use Jun. 06, 2023
  • Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors May. 23, 2023
  • Patent Title: Certain (2s)-n-[(1 s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors May. 23, 2023
  • Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors May. 23, 2023
  • Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors May. 23, 2023
  • Patent Title: Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer Mar. 28, 2023
  • Patent Title: Pcsk9 inhibitors and methods of use thereof Mar. 14, 2023
  • Patent Title: 2-(2,4,5-substituted-anilino)pyrimidine compounds Dec. 13, 2022
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of AZN in WallStreetBets Daily Discussion

AZN News

Recent insights relating to AZN

CNBC Recommendations

Recent picks made for AZN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in AZN

AZN Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view AZN Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top